Emerging treatments
Intranasal pertussis vaccine (BPZE1)
A randomized, double-blind, phase 2b trial comparing the immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, versus the existing Tdap vaccine, has shown promising results. In the group that received BPZE1, broad and consistent Bordetella pertussis-specific mucosal secretory IgA responses were observed, whereas Tdap did not induce equal responses. BPZE1 induced durable mucosal immunity and reduced nasal colonization (two key factors necessary for the prevention of transmission and reduction of epidemic pertussis cycles). Large phase 3 trials are needed to confirm these results.[37] The Food and Drug Administration (FDA) has granted fast track designation to BPZE1 for active booster immunization against pertussis. Other novel vaccines in development incorporate new antigens or antigens with more native structures and/or use different antigens or outer membrane vesicles.
Use of this content is subject to our disclaimer